Torrent Pharmaceuticals Ltd

- No specific mention of any new fundraising through debt or equity in the current call transcript. - The company has focused on debt reduction, repaying around Rs. 900 crores in the current year and expects a similar amount in the next year. - Free cash flows are projected to be strong, around Rs. 1,750 to 1,800 crores for the year. - No indications provided about plans for raising new funds via debt or equity in the near future.

- For FY'22, Torrent Pharmaceuticals is planning a normal CAPEX of Rs. 250 to 300 crores, which is primarily maintenance CAPEX; no major expansion CAPEX is planned imminently. - In the next three years, there may be some expansion CAPEX in India along with an increase in manpower, reflecting strategic investments for growth domestically. - Internationally, there are no major additions to manufacturing facilities or manpower beyond the existing facility in the US. - The company appears focused on optimizing current assets and improving market share rather than large-scale capital investments in the near term.

- India business expects around 15% IPM growth in Q1 FY'22 on a base-adjusted basis, driven by COVID-related prescriptions; similar growth anticipated in Q2. - MR productivity in India aims to increase from 8.5 lakh to 10 lakh PCPM soon, supporting growth. - Field force restructuring completed; further headcount expansion not immediate due to sufficient coverage. - Branded generics pricing in India expected to sustain 6-7% growth; Brazil pricing increases also continue around 4-5%. - Brazil market expects 9-10% pharma growth in 2021; Torrent aims to outperform market driven by branded generics and generics. - Germany business anticipated to normalize by Q3 2021 with potential for high single-digit growth as COVID impacts wane. - US business is currently subdued but aims to revert from ~$37 million towards $200 million range over medium term via ANDA filings and launches. - No major expansion CAPEX; maintenance CAPEX of Rs.250-300 crores for FY'22 expected to support operations.

- FY'22 CAPEX expected at Rs. 250-300 crores, focused on maintenance; no major expansion CAPEX planned immediately. - Employee costs increased about 8% on consolidated basis over 5-6 years; recent cost rationalization via headcount reduction. - India business growth strong, with 10% revenue growth in FY'21 and India IPM market expected to grow ~15% in Q1 FY'22 on corrected base. - MR productivity goal set to increase from ₹8.5 lakhs to ₹10 lakhs PCPM in near future, with growth potential primarily in sub-chronic and acute segments. - International markets showing recovery and growth: Brazil with 11% growth in FY'21, Germany expected to normalize with high single-digit growth by Q3 calendar year. - US business currently suboptimal at $37 million Q4 revenue; plans to restore growth via ANDA filings and launches over medium term (2-3 years). - Margins stable with gross margin guidance around 72-73%; EBITDA margin outlook for FY'22 uncertain due to COVID impacts. - Tax rate expected at 22-25% for FY'22. - Overall earnings growth likely driven by India market recovery, stable margins, and international market expansion.

The transcript from Torrent Pharmaceuticals' Q4 FY'21 earnings call does not provide explicit details regarding the current or expected order book or pending orders. However, related points include: - As of March 31, 2021, the company had 54 ANDAs (Abbreviated New Drug Applications) pending approval in the US. - The company received six tentative approvals and filed eight ANDAs in the last quarter. - Torrent aims to launch 10 to 15 ANDAs annually to grow the US business and counter price erosion. - Discussions and agreements are ongoing, such as with Lilly for Baricitinib, for new COVID-related treatments. - Despite regulatory and launch challenges in the US, the company continues active filings and expects approvals. No specific numeric order book or pending order values were mentioned in the provided pages.